Keywords: basilea, ceftobiprole, meets, ph, ii, endpoint, swiss
Basilea's ceftobiprole meets Ph II endpoint
Article | 22 January 2007
Swiss drugmaker Basilea Pharmaceutica says that its developmental antibiotic ceftobiprole has met its primary endpoint of non-inferiority to combination therapy ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
